Prestige Consumer Healthcare Locks In $400M Senior Notes at 6.250%
PBH is trading near its 52-week low of $42.62 (13% above the low).
Summary
Prestige Consumer Healthcare closed its $400 million offering of 6.250% senior notes due 2034, finalizing terms of the previously announced debt raise.
Key Events · Financing and Capital Events · PBH
-
$400M Notes Issued
A subsidiary of Prestige Consumer Healthcare, Prestige Brands, Inc., issued $400 million in 6.250% senior notes due 2034. Interest is payable semi-annually starting January 15, 2027.
-
Use of Proceeds
The proceeds are intended to fund recent acquisitions, including the $1.045 billion Breathe Right and $150 million LaCorium Health deals, and for general corporate purposes.
-
Indenture Terms
The notes are senior unsecured obligations, guaranteed by the parent and certain subsidiaries. They include optional redemption provisions starting in 2029 and a change of control offer at 101% of principal.
-
Leverage Impact
This issuance adds to the company's debt, which already includes a $1.045 billion term loan and existing senior notes. The fixed 6.250% rate locks in financing costs amid rising rates.
Analysis · PBH · Life Sciences
Prestige Consumer Healthcare has finalized its $400 million senior notes offering, locking in a 6.250% coupon. The move follows the company's recent $1.045 billion Breathe Right acquisition and $150 million LaCorium deal, adding to its debt load. Maturing in 2034, the notes are senior unsecured obligations with standard covenants and redemption options. While the offering was previously announced, the specific coupon and indenture terms are now public. The capital raise supports the company's acquisition strategy but increases leverage.
At the time of this filing, PBH was trading at $48.36 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $42.62 to $77.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.